RxDoctor Payments Data

Lindsay Overko, PA

Physician Assistant · Concord, NHNPI 1972648111

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Sanofi at 32.9% of the total. 2025 is the largest year on record at $15,521, more than ten times the $279 reported in 2021. Among physician assistant clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,138in general payments, 2019–2025

Across 285 payments — averaging $102.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$10K
  • Incyte Corporation$6K
  • Arcutis Biotherapeutics, Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • Johnson & Johnson$3K
  • AbbVie$2K
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$11,48639%
  • Speaking & faculty fees$5,37018%
  • Travel & lodging$1,0544%
  • Food & beverage$10,71937%
  • Education$5092%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,138 in reported general payments places this provider in the 95th percentile of 782 physician assistant providers in New Hampshire.

See all physician assistant providers in New Hampshire

Medicare billing

Part B allowed, 2024
$62,212
Medicare patients
444
Services billed
1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$297,375
Enbrel SureclickEtanercept11$77,205
OtezlaApremilast14$68,425
Dupixent PenDupilumab13$48,824
Dupixent SyringeDupilumab12$44,904
ZoryveRoflumilast11$9,240
Fluorouracil64$4,688
Doxycycline Hyclate21$3,228
Tacrolimus13$1,417
Metronidazole21$848
Clobetasol Propionate24$782
Minoxidil42$655
Triamcinolone Acetonide79$654
Ketoconazole38$539
Fluocinonide18$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$94$68,42514 claims
Arcutis Biotherapeutics, Inc.Zoryve$3,612$9,24011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 782 physician assistant providers in New Hampshire.

Other physician assistant in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →